Gepirone - Fabre-Kramer Pharmaceuticals
Alternative Names: Ariza; BMY 13805-1; BMY-13805; EXXUA; Gepirone ER - Fabre-Kramer Pharmaceuticals; Gepirone extended release - Fabre-Kramer Pharmaceuticals; Gepirone hydrochloride extended-release - Fabre-Kramer Pharmaceuticals; MJ-13805; Org-33062; TGFK07AD; Travivo™; Variza™Latest Information Update: 05 Oct 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Fabre-Kramer Pharmaceuticals
- Class Antidepressants; Anxiolytics; Ketones; Piperazines; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Decreased libido; Generalised anxiety disorder
Highest Development Phases
- Registered Major depressive disorder
- Phase III Decreased libido; Generalised anxiety disorder
- Discontinued Cocaine-related disorders
Most Recent Events
- 05 Oct 2023 Gepirone is available for licensing as of 05 Oct 2023. https://fabrekramer.com/ (Fabre-Kramer Pharmaceuticals website, October 2023).
- 05 Oct 2023 Chemical structure information added for salt form of the drug
- 05 Oct 2023 Phase-III clinical trials in Decreased libido (PO, Controlled release) prior to October 2023 (Fabre-Kramer Pharmaceuticals website, October 2023)